pharma · Endometrial cancer · Specific Advanced Solid Tumors · ACRV
Acrivon Therapeutics
Acrivon Therapeutics patent portfolio — 0 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Cambridge, USA HQ
2018 Founded
84 Employees
Public company Type
ACRV · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2018
- Employees
- 84
- Programs
- 4
- Drugs
- 3
- Patents
- 0
Acrivon Therapeutics patents
0 pharmaceutical patents indexed for Acrivon Therapeutics. 0 expire within 24 months.
Acrivon Therapeutics has 0 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
No patents matched
Frequently asked questions
How many patents does Acrivon Therapeutics have?
0 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Acrivon Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.